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Abstract
Background: Advances in pathophysiology and treatment of ankylosing spondylitis (AS) was recently demonstrated.
However, the effect of anti-TNF in the newly described inflammatory pathways involved pathogenesis of this disease
remains to be determined. The aim of our study was, therefore, to investigate long-term influence of anti-TNF drugs in
IL-23/IL-17 axis of AS patients and their possible correlation with treatment, clinical, laboratory and radiographic
parameters.
Methods: Eighty-six AS anti-TNF naïve patients, 47 referred for anti-TNF therapy (active-AS; BASDAI≥ 4) and 39 with
BASDAI < 4 (control-AS) were included. The active group was evaluated at baseline, 12-months and 24-months after
TNF blockade and compared at baseline to control-AS group and to 47 healthy age- and gender-matched controls.
Plasma levels of IL-17A, IL-22, IL-23 and PGE2 were measured. Non-steroidal anti-inflammatory drugs (NSAIDs) intake
were recorded every 6 months. Radiographic severity and progression was assessed by mSASSS at baseline and
24 months after therapy.
Results: At baseline, active-AS group presented higher IL-23 and PGE2 levels compared to control-AS group (p < 0.001
and p = 0.008) and to healthy controls (p < 0.001 and p = 0.02). After 24-months of TNF blockade, IL-23 and PGE2
remained elevated with higher levels compared with the healthy group (p < 0.001 and p = 0.03) in spite of
significant improvements in all clinical/inflammatory parameters (p < 0.001). Further analysis of 27 anti-TNF-treated
patients who achieved a good response (ASDAS-CRP < 2.1,with a drop ≥ 1.1) at 24-months revealed that IL-23 plasma
levels remained higher than healthy controls (p < 0.001) and higher than control-AS group with similar disease activity
(ASDAS-CRP < 2.1, p = 0.01). In active-AS group (n = 47), there was a strong correlation between IL-23 and IL-17A at
baseline, 12-months and 24-months after anti-TNF therapy (p≤ 0.001).
Conclusion: This study provides novel data demonstrating that the IL-23/IL-17 axis is not influenced by TNF blockade
in AS patients despite clinical and inflammation improvements and NSAID intake.
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Background
Spondyloarthritis (SpA) is a group of inflammatory dis-
eases in which ankylosing spondylitis (AS) is the proto-
type. Despite recent advances in pathophysiology and
treatment, this disease group is still a challenge, particu-
larly regarding the understanding of the inflammatory
pathways involved, predictors of anti-tumor necrosis
factor (anti-TNF) response, and risk factors for radio-
graphic progression.
Recently, the interleukin (IL)-23/IL-17 axis was re-
ported to have a role in SpA pathophysiology because of
promising results regarding initial efforts at blocking these
pathways in SpA [1–6]. In addition, genetic studies have
described interleukin-23 receptor (IL-23R) polymorphisms
linked to AS susceptibility [7], and higher IL-23R expres-
sion on γ/δ T cells was also associated with increased
IL-17 secretion [8]. Evidence from animal studies dem-
onstrated that misfolding of HLA-B27 generates endo-
plasmic reticulum stress with subsequent unfolded protein
response and IL-23 production by activated macrophages
and dendritic cells [1, 9]. However, the role of unfolded
protein response in modulating the production of IL-23
has not been confirmed in AS patients; instead, recent data
suggest that the lipopolysaccharide response and/or au-
tophagy of mononuclear cells may underlie the increased
IL production in this disease [10, 11]. Moreover the IL-23/
IL-23R complex, in predisposing patients, seems to induce
the activation of signal transduction and transcription, with
a consequent proliferation and terminal differentiation of
Th17 cells, resulting in IL-17 production [1, 12–15]. This
overexpression is not only a potent TNFα inducer but
also leads to the production of other proinflammatory
cytokines and chemokines [14]. Of note, nonsteroidal
anti-inflammatory drug (NSAIDs) cyclooxygenase (COX)
inhibition may influence prostaglandin E2 (PGE2) levels
with a possible impact on the IL-23/IL-17 axis and bone
formation in AS. In fact, IL-23 production is affected by
various factors, including PGE2 secreted by fibroblasts
and/or through its binding to EP-4 receptors [11, 16].
PGE2 seems to have an anabolic effect on bone via EP-2
(Prostaglandin E2 receptor 2) and EP-4 (Prostaglandin E2
receptor 4) receptors and affects human tendon cell differ-
entiation [17, 18].
In this context, clinical practice and registry studies
have suggested that the isolated use of anti-TNFα is un-
able to reduce radiographic progression in AS, suggesting
that other pathways may be involved [19–21]. Subsequent
studies have inferred a possible benefit of NSAID con-
comitant use and radiographic progression. In 2005
Wanders et al. [22] demonstrated that the strategy of
continuous use of NSAIDs reduces radiographic pro-
gression in symptomatic patients with AS, independ-
ently of baseline values of radiographic damage or
disease activity variables. In addition, a protective effect
of a higher NSAID intake over time was associated with
retarded radiographic progression in AS patients from
a prospective SpA inception cohort in Germany [23].
More recently, Appel et al. [24] described increased
IL-23-positive cell expression in subchondral bone mar-
row and in fibrous tissue in the spine of patients with a
longstanding history of AS. In addition, it was demon-
strated that the enthesis in a spondyloarthropathy model
is a functional IL-23-responsive anatomic site containing
primed IL-23 resident cells promoting IL-17 and IL-22
expression [25].
In spite of this compelling evidence regarding the rele-
vance of the IL-23/IL-17 immune axis in AS pathogen-
esis, there are no data on the long-term influence of
TNF blockade in this axis concerning a possible syner-
gistic or independent effect of these cytokines.
This study therefore aims to investigate the influence
of anti-TNF therapy in the IL-23/IL-17 axis of AS patients
and its possible correlation with clinical, inflammatory
markers, treatment, and radiographic parameters.
Methods
Subjects
Eighty-six AS anti-TNF-naïve patients, aged ≥18 to <65 years,
who fulfilled the modified AS New York criteria in regular
rheumatology outpatient follow-up care were included [26].
At entry, 47 consecutive AS patients (active-AS group) were
referred to the Infusion Center to start anti-TNFα ther-
apy, according to the Assessment of SpondyloArthritis
International Society (ASAS) consensus statement [27].
They were classified with active disease (Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) ≥4) despite
treatment with at least two NSAIDs at a maximal tolerable
dose with or without disease-modifying antirheumatic drugs
(DMARDs) (methotrexate, sulphasalazine, or leflunomide)
at standard doses for at least 6 months [27]. Forty-seven
sex-matched and age-matched healthy individuals com-
prised the healthy control group (healthy controls). Add-
itionally, the AS patient control group of 39 consecutive AS
patients with BASDAI <4 under NSAID and/or traditional
DMARDS were also evaluated at entry (control-AS group).
Study design
This study comprises: a cross-sectional evaluation com-
paring 47 active-AS patients (BASDAI ≥4), 39 AS patients
with BASDAI <4 (control-AS group), and 47 healthy indi-
viduals at baseline (healthy controls); and a longitudinal
evaluation of 47 active-AS patients followed with clinical,
radiographic, and laboratorial parameters at baseline and
12 and 24 months of anti-TNF therapy.
This study was approved by the Local Ethics Commit-
tee on Human Research at the University of São Paulo
(CAPPesq). All participants gave written informed con-
sent in accordance with the Declaration of Helsinki.
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Clinical outcomes and NSAID use
Clinical outcomes included the C-reactive protein Anky-
losing Spondylitis Disease Activity Score (ASDAS-CRP),
BASDAI, Bath Ankylosing Spondylitis Functional Index
(BASFI), Bath Ankylosing Spondylitis Metrology Index
(BASMI), and AS quality-of-life questionnaire (ASQoL)
[28]. These clinical parameters were performed at base-
line and 12 and 24 months of follow-up. Concomitant
medications were recorded every 6 months and NSAID
intake (drug, dose, and frequency of use) was standard-
ized to 0–100 as recommended by the ASAS [29].
Definitions of baseline clinical activity and follow-up
Anti-TNF response
Active disease was defined as BASDAI ≥4 at entry and,
for follow-up, ASDAS-CRP ≥2.1. An anti-TNF response
was classified after 24 months of anti-TNF treatment
according to ASDAS criteria into responders (ASDAS-
CRP <2.1 with a drop ≥1.1 from baseline) and nonre-
sponders (ASDAS-CRP ≥2.1 or a drop <1.1 from base-
line) [30].
Laboratory assessment of cytokine levels and
inflammation
Plasma samples were obtained from all active-AS patients
(n = 47) immediately before anti-TNF infusion. The la-
boratory assessment was performed at baseline and 12
and 24 months after treatment. The control-AS group
(n = 39) and healthy controls (n = 47) underwent a sin-
gle plasma withdrawal at baseline. All samples were im-
mediately frozen and stored at –80 °C. IL-17, IL-22,
and IL-23 were measured by LUMINEX 200™ technol-
ogy (Luminex B.V., Oosterhout, the Netherlands) using
a Millipore kit (EMD Millipore, Darmstadt, Germany)
supplied with the following minimal detection concentra-
tion (MinDC): IL-17A, MinDC= 2.1 pg/ml; IL-22, MinDC
= 0.021 ng/ml; and IL-23, MinDC = 0.098 ng/ml. All
samples were tested in duplicate. For PGE2, enzyme-
linked immunosorbent assay methodology was employed
using a USCN kit (Cloud-Clone Corp, 1304 Langham
Creek Dr, Houston, Tx 77084, USA)(sensitivity of 1.52 pg/
ml) and a Stat Fax-2.100 (Awareness Technology, Inc.
P.O. Drawer 1679 Palm City, FL 34991 USA) reader. In-
flammatory response was evaluated by the CRP level (mg/
l) and the erythrocyte sedimentation rate (ESR, mm/hour).
The frequency of patients’ samples ≥MinDC was 72 % for
IL-23, 100 % for PGE2, 36 % for IL-17, and 8 % for IL-22.
Radiological assessment
Structural damage was scored on digital X-ray images of
the lumbar and cervical spine according to the modified
Stoke Ankylosing Spondylitis Spine Score (mSASSS) at
baseline for all AS patients and at 24 months after anti-
TNF treatment [31]. Two blinded and independent
expert investigators (one musculoskeletal radiologist and
one rheumatologist) performed the score evaluation.
The baseline and follow-up X-ray images were scored at
the same time by two investigators blinded to time point,
clinical, and demographic features.
Radiographic spinal progression after 2 years was defined
according to an increase by 2 or more units in the
mSASSS.
The intraclass correlation coefficients (two-way random
and absolute agreement in SPSS 20 (IBM Corporation - 1
New Orchard Road, Armonk, NY, 10504, USA)) between
the two readers regarding mSASSS status was 0.997 (95 %
confidence interval (CI) 0.995–0.998) at baseline and 0.998
(95 % CI 0.996–0.999) at 24 months. Agreement regarding
change in the mSASSS was 0.951 (95 % CI 0.914–0.972).
Statistical analysis
Statistical analysis was performed using SPSS 20. Based
on a previous study comparing serum levels of IL-23
and IL-17 in AS patients and healthy controls [32], a
minimum sample size of seven individuals per group was
calculated. The current study sample size ensured >95 %
power to detect similar differences in AS patients and
healthy controls. Results are presented as the mean and
standard deviation (SD) for continuous variables, the me-
dian and 25–75 % interquartile range (IQR) for nonpara-
metric data, and percentages for categorical variables. Data
for continuous variables were compared by the t test or
Mann–Whitney U test as appropriate. Clinical and labora-
torial data at baseline, 12 and 24 months were analyzed by
Friedman repeated-measures analysis of variance on ranks
followed by a post-hoc analysis by Tukey test to determine
which groups in the sample differ. The statistical analysis
used the appropriate tests according to data distribution,
and for cytokines a nonparametric test was used. Multiple
linear regression analysis was performed, including all clin-
ical differences between the active-AS group and the
control-AS group, to infer differences in cytokine and
PGE2 concentrations. Radiographic progression and anti-
TNF response associated factors were analyzed (baseline
parameters and their changes after 12 and 24 months of
treatment). Spearman’s rank was applied for correlation
analysis. Statistical significance was established at p <0.05.
Results
Baseline demographic and clinical characteristics of AS
patients and healthy controls
Active-AS patients (BASDAI ≥4) and the healthy control
group were comparable regarding age (38.02 ± 11.09 years
vs. 37.74 ± 10.95 years, p = 0.90), male gender (74 % vs.
74 %, p = 1.00), and Caucasian predominance (89 % vs.
76 %, p = 0.17). The comparison between the control-AS
group (BASDAI <4) and the healthy controls showed a
similar male gender frequency (74 % vs. 74 %, p = 1.00),
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Caucasian predominance (74 % vs. 76 %, p = 1.00), and
a higher mean age (49.51 ± 10.53 years vs. 37.74 ±
10.95 years, p < 0.001).
Baseline demographic features for the active-AS and
control-AS groups are presented in Table 1. Active-AS
patients were younger (p <0.001) and had shorter disease
duration (p = 0.007), worse clinical outcomes measured
by the ASDAS-CRP, BASFI, and ASQoL (p <0.001),
higher levels of CRP and ESR (p <0.001), lower mSASSS
(p <0.001), and lower BASMI (p = 0.03) than control-AS
patients. The proportion of patients using methotrexate
(mean dose of 20.76 ± 4.67 mg/week) was higher in the
active-AS group than the control-AS group (p <0.001).
Baseline cytokine plasma levels in AS patient groups and
the healthy control group
The active-AS group presented significantly higher IL-23
and PGE2 plasma levels compared with the control-AS
group (p <0.001 and p = 0.008) and with healthy controls
(p <0.001 and p= 0.02). No difference was observed in IL-
23 and PGE2 plasma levels comparing the control-AS group
with the healthy controls (p= 0.57 and p = 0.99) (Table 2).
With regard to IL-17 and IL-22, comparable plasma
levels were observed evaluating active-AS vs. control-AS
groups (p = 0.45 and p = 0.68), active-AS vs. healthy
control groups (p = 0.48 and p = 0.47), and control-AS vs.
healthy control groups (p = 0.90 and p = 0.78) (Table 2).
Multiple linear regression analysis was performed, in-
cluding all clinical differences between the active-AS
group and the control-AS group (age, disease duration,
BASFI, BASMI, ASQoL, mSASSS, and methotrexate use),
and no factor was associated with differences in cytokine
and PGE2 concentrations.
Longitudinal clinical and laboratorial parameter changes in
the active-AS group after 24 months of anti-TNF therapy
At entry, 32 (68 %) patients started with infliximab (the
first available TNF blockade at our center during the
study period), 13 (28 %) patients with adalimumab, and
two (4 %) patients with etanercept at standard doses.
Seventeen patients switched to another anti-TNF because
of inefficacy or adverse events during the 24 months of
follow-up. All patients who started the study were
followed until the end (no dropout).
After 2 years of TNF blockade, there was a significant
improvement in all clinical parameters evaluated and a
concomitant reduction in ESR and CRP was observed
(p <0.001) (Table 3). Of note, IL-23 and PGE2 plasma
levels remained elevated without significant changes com-
paring baseline vs. 12 months vs. 24 months (p = 0.38 and
Table 1 Clinical and demographic data of ankylosing spondylitis patients at baseline
Ankylosing spondylitis (n = 86)
Variable Active-AS Control-AS p value
(BASDAI ≥4; n = 47) (BASDAI <4; n = 39)
Gender, male (%) 35 (74 %) 29 (74 %) 1.00
Age (years) 38.0 ± 11.1 49.5 ± 10.5 <0.001
Caucasian (%) 42 (89 %) 29 (74 %) 0.09
Peripheral involvement (%) 31 (66 %) 23 (59 %) 0.65
HLA-B27 positive (%) 82 % 90 % 0.36
Disease duration (years) 10.8 ± 4.5 17.6 ± 8.9 0.007
ASDAS-CRP 3.9 ± 1.0 2.0 ± 0.8 <0.001
BASFI 5.8 ± 2.3 3.8 ± 2.1 <0.001
BASMI 4.5 ± 2.7 5.8 ± 2.7 0.03
ASQoL 12.6 ± 4.8 5.3 ± 4.1 <0.001
CRP (mg/l) 29.7 ± 39.6 4.6 ± 3.5 <0.001
ESR (mm/hour) 29.7 ± 23.3 6.9 ± 6.6 <0.001
mSASSS 15.8 ± 18.9 37.9 ± 25.5 <0.001
NSAID intake score (0–100) 70.3 ± 44.8 68.3 ± 41.4 0.77
Methotrexate (%) 23 (48 %) 2 (0.5 %) <0.001
Sulphasalazine (%) 27 (57 %) 21 (53 %) 0.83
Leflunomide (%) 2 (4.2 %) 1 (0.02 %) 1.00
All values are expressed as the mean ± standard deviation, except proportions (%)
Nonparametric tests were performed for data that failed the normal distribution
AS ankylosing spondylitis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score-C-reactive protein, ASQoL Ankylosing Spondylitis Quality of Life, BASDAI Bath
Ankylosing Spondylitis Disease Activity Index, BASFI Bath AS Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, ESR
erythrocyte sedimentation rate, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, NSAID nonsteroidal anti-inflammatory drug
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p = 0.98). Levels of these cytokines at 24 months were
higher than those observed for the healthy control group
(p <0.001 and p = 0.03), whereas no change in IL-17A or
IL-22 plasma levels (p >0.05) were detected during TNF
blockade, with levels comparable with the healthy control
group at 24 months (p >0.05) (Table 3).
The NSAID intake score exhibited a significant de-
crease after anti-TNF treatment (p <0.01) (Table 3) with-
out a significant correlation between NSAID intake scores
and PGE2 plasma levels at baseline (r = 0.07), 12 months
(r=–0.20), and 24 months (r=–0.28) of treatment (p >0.05).
After 2 years of treatment with anti-TNF, 27 active-AS
patients (57.5 %) achieved a good clinical anti-TNF re-
sponse (responders). Comparing anti-TNF responders
with nonresponders at baseline, there was no significant
difference in median (IQR) for IL-17A (2.06 (1.26–3.04)
pg/ml vs. 1.53 (0.75–2.17) pg/ml, p = 0.10), IL-22 (0.00
(0.00–00) pg/ml vs. 0.00 (0.00–0.00) ng/ml, p = 0.75), IL-23
(0.08 (0.04–0.13) pg/ml vs. 0.07 (0.05–0.31) ng/ml, p =
0.70), and PGE2 (19.07 (4.25–83.16) pg/ml vs. 36.34
(7.55–127.89) pg/ml, p = 0.51).
After 24 months of TNF blockade, active-AS responders
(ASDAS-CRP <2.1) had higher plasma levels of IL-17A
compared with nonresponders (ASDAS-CRP ≥2.1) (p =
0.03). No difference was observed in IL-22, IL-23, and
PGE2 plasma levels (p >0.05) (Table 4).
Further analysis of all cytokines levels at 24 months
showed that only IL-23 plasma levels were higher in active-
AS patients who responded to anti-TNF therapy compared
with the control-AS group with similar disease activity
Table 2 Baseline cytokine levels in ankylosing spondylitis patients and healthy controls
Ankylosing spondylitis (n = 86) Healthy controls (n = 47)
Cytokine Active-AS Control-AS p valuea p valueb p valuec
(BASDAI ≥4; n = 47) (BASDAI <4; n = 39)
IL-17A (pg/ml) 1.62 (1.06–2.98) 1.57 (1.04–2.17) 0.45 1.57 (1.04–2.17) 0.48 0.90
IL-22 (ng/ml) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.68 0.00 (0.00–0.00) 0.47 0.78
IL-23 (ng/ml) 0.08 (0.04–0.17) 0.03 (0.01–0.08) <0.001 0.02 (0.00–0.05) <0.001 0.57
PGE2 (pg/ml) 19.46 (5.41–102.58) 7.67 (3.96–24.73) 0.008 7.66 (3.30–30.32) 0.02 0.99
All values are expressed as the median (25–75 % interquartile range)
aActive-AS vs. control-AS
bActive-AS vs. healthy controls
cControl-AS vs. healthy controls
AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, IL interleukin, PGE2 prostaglandin E2
Table 3 Cytokines, inflammatory markers, and clinical parameters in active-AS patients undergoing anti-TNF therapy vs. healthy
controls
Active-AS patients Healthy controls (n = 47)
Variable Baseline (n = 47) 12 months (n = 47) 24 months (n = 47) p valuea p valueb
ESR (mm/hour) 29.70 ± 23.32 9.59 ± 12.10 10.53 ± 13.90 <0.001 NA
CRP (mg/l) 29.71 ± 39.56 7.57 ± 13.50 5.13 ± 6.23 <0.001 NA
mSASSS 15.83 ± 18.73 NA 19.49 ± 19.61 <0.001 NA
ASDAS-CRP 3.93 ± 1.04 2.08 ± 1.12 1.93 ± 1.11 <0.001 NA
BASFI 5.80 ± 2.33 3.60 ± 2.97 3.18 ± 2.95 <0.001 NA
BASMI 4.53 ± 2.70 3.70 ± 2.72 3.34 ± 2.56 <0.001 NA
ASQoL 12.59 ± 4.83 6.57 ± 5.51 5.83 ± 5.81 <0.001 NA
NSAID intake (0–100) 70.26 ± 44.78 62.43 ± 47.56 45.16 ± 46.37 <0.01 NA
IL-17A (pg/ml) 1.62 (1.06–2.98) 1.58 (1.14–3.52) 1.69 (0.78–3.46) 0.78 1.57 (1.04–2.17) 0.96
IL-22 (ng/ml) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.87 0.00 (0.00–0.00) 0.59
IL-23 (ng/ml) 0.08 (0.04–0.17) 0.04 (0.02–0.17) 0.06 (0.03–0.15) 0.38 0.02 (0.00–0.05) <0.001
PGE2 (pg/ml) 19.46 (5.41–102.58) 23.73 (4.72–102.82) 35.50 (5.88–75.82) 0.98 7.66 (3.30–30.32) 0.03
Values expressed as mean ± standard deviation or median (25–75 % interquartile range)
Nonparametric tests were performed for data that failed the normal distribution
aActive-AS at baseline vs. 12 months vs. 24 months by analysis of variance
bActive-AS after 24 months TNF blockade vs. healthy controls
AS ankylosing spondylitis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score-C-reactive protein, ASQoL Ankylosing Spondylitis Quality of life, BASFI Bath
Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, IL
interleukin, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, NA not analyzed, NSAID nonsteroidal anti-inflammatory drug, PGE2 prostaglandin E2,
TNF tumor necrosis factor
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(ASDAS-CRP <2.1) (p = 0.01) and with the healthy con-
trol group (p <0.001) (Table 4).
Correlation analysis of clinical parameters, inflammatory
markers, and cytokine plasma levels in active-AS patients
A significant correlation was observed between IL-23 and
IL-17 levels at baseline (r = 0.64, p <0.001), 12 months
(r = 0.47, p = 0.001), and 24 months (r = 0.61, p <0.001).
IL-23 was also correlated with PGE2 at 12 months (r =
0.45, p = 0.001) and 24 months (r = 0.33, p = 0.02). At
24 months, PGE2 levels were also correlated with the
ESR (r = 0.32, p = 0.03), CRP (r = 0.32, p = 0.03), and
ASDAS-CRP (r = 0.28, p = 0.04).
Radiographic progression in active-AS patients
There was a significant increase in mSASSS score after
24 months (15.83 ± 18.73 units vs. 19.49 ± 19.61 units,
p <0.001) (Table 3). Twenty-seven active-AS patients
(57.5 %) increased mSASSS ≥2 units at 24 months
(progressors). The progressor group had a mean in-
crease of 6.35 ± 5.88 units in the score, with an initial
mSASSS of 18.37 ± 17.93 units and a final score of
24.44 ± 18.61 units (p <0.001). The group of nonpro-
gressors (20 patients) had a mean average increase of
0.67 ± 0.86 units in the score, with an initial mSASSS
of 12.40 ± 19.07 units and a final score of 12.80 ± 19.40
units (p >0.05). Initial mSASSS was similar in progres-
sor and nonprogressor patients (p >0.05). Analysis of
cytokines, inflammatory markers and clinical parame-
ters (baseline and their changes after 12 and 24 months
of treatment) could not identify any risk factors for
radiographic progression in this population (p >0.05).
Discussion
This study demonstrated that elevated plasma levels of
IL-23 and PGE2 in active-AS patients are independent
of TNF blockade and clinical improvement, reinforcing
the relevance of these ILs in AS pathogenesis.
The great advantage of this report is the longitudinal
follow-up of active-AS patients compared with control-
AS (BASDAI <4) and healthy control groups, allowing a
more precise definition of the possible association of clin-
ical activity and cytokine levels. We confirmed the previ-
ous observation that there are higher levels of IL-23 in AS
patients compared with healthy controls supporting a role
for these cytokines in AS inflammation [32–34]. Two
other investigators reported contrasting data but their
analysis did not take into account the distinct levels of
disease activity [35, 36]. In fact, we and others have dem-
onstrated that IL-23 levels were higher in active-AS pa-
tients compared with the control-AS group (BASDAI <4)
and the latter was comparable with the healthy control
group [32].
In addition, concomitant evaluation of IL-17A, IL-22, IL-
23, and PGE2 in AS patients undergoing anti-TNF ther-
apy performed herein offered a unique opportunity to
discriminate how the cytokines interact with the TNF
pathway. The lack of information regarding TNF blockade
therapy in former studies precludes a definitive conclusion
about the relationship with disease progression [32–34].
The only available report of an association between TNF
blockade and IL-23/IL-17 is a short-term evaluation
with a small sample size of only eight nonpsoriatic SpA
patients [35].
A study limitation was the lack of cytokine levels in
tissue samples that could have brought additional informa-
tion about the sites of inflammation. Furthermore, our data
may underestimate possible elevations of IL-17 and IL-22
since plasma levels were below the minimal detection con-
centrations for most patients. In fact, reliable detection of
IL-17 and IL-22 plasma levels remains a challenge.
The novel demonstration that PGE2 levels in active-AS
patients were higher than those of control-AS patients, in
Table 4 ASDAS-CRP comparison of cytokines in active-AS group responders and nonresponders after 24 months of TNF blockade,
control-AS group, and healthy controls
Control-AS group
Active-AS patients after anti-TNF (ASDAS-CRP <2.1; n = 21) Healthy controls (n = 47)
Cytokine Responders Nonresponders p valuea p valueb p valuec
(ASDAS-CRP <2.1; n = 27) (ASDAS-CRP ≥2.1; n = 20)
IL-17A (pg/ml) 2.17 (0.86–3.99) 1.04 (0.66–1.82) <0.05 1.29 (1.10–2.17) 0.07 1.57 (1.04–2.17) 0.23
IL-22 (ng/ml) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.99 0.00 (0.00–0.00) 0.71 0.00 (0.00–0.00) 0.64
IL-23 (ng/ml) 0.09 (0.03–0.21) 0.05 (0.02–0.13) 0.49 0.02 (0.01–0.06) 0.01 0.02 (0.00–0.05) <0.001
PGE2 (pg/ml) 13.03 (4.30–56.59) 45.17 (10.92–93.76) 0.10 8.13 (4.17–23.07) 0.11 7.66 (3.30–30.32) 0.33
All values are expressed as the median (25–75 % interquartile range)
aActive-AS group responders after 24 months of TNF blockade vs. nonresponders
bActive-AS group responders after 24 months of TNF blockade vs. control-AS group (ASDAS-CRP <2.1)
cActive-AS group responders after 24 months of TNF blockade vs. healthy controls
AS ankylosing spondylitis, ASDAS-CRP C-reactive protein Ankylosing Spondylitis Disease Activity Score, IL interleukin, PGE2 prostaglandin E2, TNF tumor
necrosis factor
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spite of comparable NSAID intake score, supports the no-
tion that PGE2 production does not occur exclusively
through COX-1 and COX-2 [16, 17, 37]. Possible signifi-
cant role of this cytokine in inflammation is evidenced by
the fact that active-AS patients had higher levels of PGE2
than healthy controls and that the control-AS group
(BASDAI <4) had comparable levels with the healthy
group.
Remarkably, levels of IL-23 and PGE2 remained per-
sistently elevated during treatment with anti-TNF drugs,
regardless of significant clinical and laboratory parameter
improvement. The persistent elevation of these cytokines
in the plasma suggests that anti-TNF therapy may not be
sufficient for completely blocking the inflammatory process
seen in AS. In fact, the relevance of the IL-23/IL-17 path-
way in AS pathogenesis is supported by a recent study that
demonstrated IL-23-responsive cells (expressing IL-23R) at
the tendon/bone interface in a murine model, in which
overproduction of IL-23 caused periosteal and entheseal
pathology similar to that seen in patients with SpA [25].
Moreover, it was demonstrated that IL-23 is increased
locally in involved target organs, such as the gut [38].
Concerning PGE2 levels, there is evidence that prosta-
glandins, particularly PGE2, have an impact on bone me-
tabolism [17, 39, 40], and two previous genetic studies
have demonstrated the association of the PTGER4 gene
with increased predisposition to AS and radiographic pro-
gression [41, 42]. The observed PGE2 correlation with
disease activity (ASDAS-CRP) and inflammatory markers
(ESR and CRP) at 24 months, regardless of a significant
reduction in NSAIDs, reinforces the hypothesis of an
alternative regulation for this cytokine in the IL-23/IL-17
axis.
Of note, IL-23 can stimulate innate immune cells to
produce other proinflammatory cytokines, including
TNF, IL-22, and IL-17 family members [15, 43]. Previous
studies have also shown an increase of circulating Th17
cells in blood and high levels of IL-17 in AS patients [8,
31–34, 37, 44]. Contrary to expectation, IL-17 and IL-22
were not elevated in the active patients evaluated herein.
However, there was a strong correlation of IL-23 with
IL-17 plasma levels in active-AS patients undergoing
TNF therapy throughout the study. Intriguingly, higher
IL-17A levels in active-AS responders compared with
nonresponders were observed. However, the interpret-
ation of these data should be made with caution and we
should consider that IL-17 is a TNF inducer that could
lead to increased TNF production and a possible better
response to TNF blockade.
Previous studies showed a high variability in the per-
centage of progressors and nonprogressors [45, 46]. It
was suggested that the presence of prior syndesmophytes,
male gender, smoking, HLA-B27 positivity, longer disease
duration, and elevated inflammatory markers are possible
risk factors for new bone formation in AS [45, 47, 48].
Among the studied variables, we could not identify factors
associated with radiographic progression in active-AS
under anti-TNF therapy, reinforcing the possibility of
multifactorial pathways contributing to this outcome. The
sample size of the study did not allow reliable statements
about prediction of radiographic progression.
The moderate correlation between IL-23 and PGE2,
the persistent high IL-23/PGE2 levels, and the significant
radiographic progression in spite of apparent clinical
control support the hypothesis that current clinical dis-
ease activity and inflammatory markers, such as the ESR
and CRP, may not be sufficient to guide treat-to-target
therapy in AS [49, 50]. In fact, the lack of magnetic reson-
ance imaging evaluation precluded a more accurate defin-
ition about persistent inflammation in these patients.
Of note, even active-AS anti-TNF responders (ASDAS-
CRP <2.1) retained high IL-23 levels. This finding
strengthens the evidence for a lack of upstream IL-23/
IL-17 blockade in AS patients treated with TNF blockade.
Moreover, new therapies such as a monoclonal antibody
against the common p40 subunit of IL-23 and IL-12
(Ustekinumab) and an anti-IL-17A monoclonal antibody
(Secukinumab) show promising results in AS [5, 6].
Conclusions
This study provides novel data demonstrating that the
IL-23/IL-17 axis is not influenced by TNF blockade in
AS patients despite clinical and inflammation improve-
ments and NSAID intake.
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